Author

S. Aras

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Assay:ChIP-seq· 1 Research Focus:chromatin & epigenetic regulation· 1 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

N. Purandare· 2 shared A. D. Berezovsky· 1 shared A. deCarvalho· 1 shared A. Fribley· 1 shared A. M. Chinnaiyan· 1 shared A. Parolia· 1 shared B. K. Verma· 1 shared C. Hou· 1 shared

Activity by Year

2023-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 17 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

N. Purandare

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

NSD2 is a requisite subunit of the AR/FOXA1 neo-enhanceosome in promoting prostate tumorigenesis

A. Parolia, S. Eyunni, B. K. Verma, E. Young, L. Liu, J. George, S. Aras, C. K. Das, R. Mannan, R. ur Rasool, J. Luo, S. E. Carson, E. Mitchell-Velasquez, Y. Liu, L. Xiao, , I. A. Asangani

This study identifies NSD2 as a critical component of the AR neo-enhanceosome in prostate cancer, showing its role in AR enhancer circuitry and tumor progression.

Nature Genetics · Sep 9, 2024Peer-reviewedCancer Biology

Impact of genomic background and developmental state on signaling pathways and response to therapy in Glioblastoma patient-derived cells

A. D. Berezovsky, O. Nuga, I. Datta, K. Bergman, T. Sabedot, K. Gurdziel, S. Irtenkauf, L. Hasselbach, Y. Meng, C. Mueller, E. Petricoin, S. Brown, N. Purandare, S. Aras, T. Mikkelsen, , A. deCarvalho

This study examines how genomic background and developmental state affect signaling pathways and therapy response in GBM patient-derived cells, finding that differentiation increases TMZ resistance and activates DNA-damage interferon responses.

bioRxiv · Mar 14, 2024 · PreprintCancer Biology

MNRR1 activation by nitazoxanide abrogates lipopolysaccharide- induced preterm birth in mice

N. Purandare, N. Gomez-Lopez, M. Arenas-Hernandez, J. Galaz, R. Romero, Y. Xi, A. Fribley, L. I. Grossman, S. Aras

The paper shows that nitazoxanide prevents preterm birth in mice by activating MNRR1, which counteracts inflammation caused by intra-amniotic LPS.

bioRxiv · Jan 30, 2023 · PreprintImmunology